Exploratory Biomarker Analysis in the Phase III L-MOCA Study of Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer
BMC MEDICINE(2024)
Key words
Platinum-sensitive relapsed ovarian cancer,Olaparib,PD-L1 expression,BRCA1/2,PARP inhibitors,Homologous recombination deficiency,L-MOCA trial,Biomarker
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined